18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma

Kung Chu Ho, Chyong Huey Lai, Tzu I. Wu, Koon Kwan Ng, Tzu Chen Yen, Gigin Lin, Ting Chang Chang, Chun Chieh Wang, Swei Hsueh, Huei Jean Huang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: Uterine carcinosarcomas clinically confined to the uterus usually harbor occult metastases. We conducted a pilot study to evaluate the value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in uterine carcinosarcoma. Methods: Patients with histologically confirmed uterine carcinosarcoma were enrolled. Abdominal and pelvic magnetic resonance imaging (MRI)/whole-body computed tomography (CT) scan, and whole-body 18F-FDG PET or PET/CT were undertaken for primary staging, evaluating response, and restaging/post-therapy surveillance. The clinical impact of 18F-FDG PET was determined on a scan basis. Results: A total of 19 patients were recruited and 31 18F-FDG PET scans (including 8 scans performed on a PET/CT scanner) were performed. Positive impacts of scans were found in 36.8% (7/19) for primary staging, 66.7% (2/3) for monitoring response, and 11.1% (1/9) for restaging/post-therapy surveillance. PET excluded falsely inoperable disease defined by MRI in two patients. Aggressive treatment applying to three patients with PET-defined resectable stage IVB disease seemed futile. Two patients died of disease shortly after salvage therapy restaged by PET. With PET monitoring, one stage IVB patient treated by targeted therapy only was alive with good performance. Using PET did not lead to improvement of overall survival of this series compared with the historical control (n = 35) (P = 0.779). Conclusions: The preliminary results suggest that 18F-FDG PET is beneficial in excluding falsely inoperable disease for curative therapy and in making a decision on palliation for better quality of life instead of aggressive treatment under the guidance of PET. PET seems to have limited value in post-therapy surveillance or restaging after failure.

Original languageEnglish
Pages (from-to)484-492
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume35
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

Fingerprint

Carcinosarcoma
Fluorodeoxyglucose F18
Positron-Emission Tomography
Therapeutics
Magnetic Resonance Imaging
X-Ray Computed Tomography Scanners
Whole Body Imaging
Salvage Therapy
Uterus
Decision Making

Keywords

  • F-FDG
  • Clinical impact
  • Malignant mixed müllerian tumor
  • PET
  • Uterine carcinosarcoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. / Ho, Kung Chu; Lai, Chyong Huey; Wu, Tzu I.; Ng, Koon Kwan; Yen, Tzu Chen; Lin, Gigin; Chang, Ting Chang; Wang, Chun Chieh; Hsueh, Swei; Huang, Huei Jean.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 3, 03.2008, p. 484-492.

Research output: Contribution to journalArticle

Ho, KC, Lai, CH, Wu, TI, Ng, KK, Yen, TC, Lin, G, Chang, TC, Wang, CC, Hsueh, S & Huang, HJ 2008, ' 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma', European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 3, pp. 484-492. https://doi.org/10.1007/s00259-007-0533-z
Ho, Kung Chu ; Lai, Chyong Huey ; Wu, Tzu I. ; Ng, Koon Kwan ; Yen, Tzu Chen ; Lin, Gigin ; Chang, Ting Chang ; Wang, Chun Chieh ; Hsueh, Swei ; Huang, Huei Jean. / 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. In: European Journal of Nuclear Medicine and Molecular Imaging. 2008 ; Vol. 35, No. 3. pp. 484-492.
@article{c500e922ced44feaa46f1bb55151652d,
title = "18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma",
abstract = "Purpose: Uterine carcinosarcomas clinically confined to the uterus usually harbor occult metastases. We conducted a pilot study to evaluate the value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in uterine carcinosarcoma. Methods: Patients with histologically confirmed uterine carcinosarcoma were enrolled. Abdominal and pelvic magnetic resonance imaging (MRI)/whole-body computed tomography (CT) scan, and whole-body 18F-FDG PET or PET/CT were undertaken for primary staging, evaluating response, and restaging/post-therapy surveillance. The clinical impact of 18F-FDG PET was determined on a scan basis. Results: A total of 19 patients were recruited and 31 18F-FDG PET scans (including 8 scans performed on a PET/CT scanner) were performed. Positive impacts of scans were found in 36.8{\%} (7/19) for primary staging, 66.7{\%} (2/3) for monitoring response, and 11.1{\%} (1/9) for restaging/post-therapy surveillance. PET excluded falsely inoperable disease defined by MRI in two patients. Aggressive treatment applying to three patients with PET-defined resectable stage IVB disease seemed futile. Two patients died of disease shortly after salvage therapy restaged by PET. With PET monitoring, one stage IVB patient treated by targeted therapy only was alive with good performance. Using PET did not lead to improvement of overall survival of this series compared with the historical control (n = 35) (P = 0.779). Conclusions: The preliminary results suggest that 18F-FDG PET is beneficial in excluding falsely inoperable disease for curative therapy and in making a decision on palliation for better quality of life instead of aggressive treatment under the guidance of PET. PET seems to have limited value in post-therapy surveillance or restaging after failure.",
keywords = "F-FDG, Clinical impact, Malignant mixed m{\"u}llerian tumor, PET, Uterine carcinosarcoma",
author = "Ho, {Kung Chu} and Lai, {Chyong Huey} and Wu, {Tzu I.} and Ng, {Koon Kwan} and Yen, {Tzu Chen} and Gigin Lin and Chang, {Ting Chang} and Wang, {Chun Chieh} and Swei Hsueh and Huang, {Huei Jean}",
year = "2008",
month = "3",
doi = "10.1007/s00259-007-0533-z",
language = "English",
volume = "35",
pages = "484--492",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma

AU - Ho, Kung Chu

AU - Lai, Chyong Huey

AU - Wu, Tzu I.

AU - Ng, Koon Kwan

AU - Yen, Tzu Chen

AU - Lin, Gigin

AU - Chang, Ting Chang

AU - Wang, Chun Chieh

AU - Hsueh, Swei

AU - Huang, Huei Jean

PY - 2008/3

Y1 - 2008/3

N2 - Purpose: Uterine carcinosarcomas clinically confined to the uterus usually harbor occult metastases. We conducted a pilot study to evaluate the value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in uterine carcinosarcoma. Methods: Patients with histologically confirmed uterine carcinosarcoma were enrolled. Abdominal and pelvic magnetic resonance imaging (MRI)/whole-body computed tomography (CT) scan, and whole-body 18F-FDG PET or PET/CT were undertaken for primary staging, evaluating response, and restaging/post-therapy surveillance. The clinical impact of 18F-FDG PET was determined on a scan basis. Results: A total of 19 patients were recruited and 31 18F-FDG PET scans (including 8 scans performed on a PET/CT scanner) were performed. Positive impacts of scans were found in 36.8% (7/19) for primary staging, 66.7% (2/3) for monitoring response, and 11.1% (1/9) for restaging/post-therapy surveillance. PET excluded falsely inoperable disease defined by MRI in two patients. Aggressive treatment applying to three patients with PET-defined resectable stage IVB disease seemed futile. Two patients died of disease shortly after salvage therapy restaged by PET. With PET monitoring, one stage IVB patient treated by targeted therapy only was alive with good performance. Using PET did not lead to improvement of overall survival of this series compared with the historical control (n = 35) (P = 0.779). Conclusions: The preliminary results suggest that 18F-FDG PET is beneficial in excluding falsely inoperable disease for curative therapy and in making a decision on palliation for better quality of life instead of aggressive treatment under the guidance of PET. PET seems to have limited value in post-therapy surveillance or restaging after failure.

AB - Purpose: Uterine carcinosarcomas clinically confined to the uterus usually harbor occult metastases. We conducted a pilot study to evaluate the value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in uterine carcinosarcoma. Methods: Patients with histologically confirmed uterine carcinosarcoma were enrolled. Abdominal and pelvic magnetic resonance imaging (MRI)/whole-body computed tomography (CT) scan, and whole-body 18F-FDG PET or PET/CT were undertaken for primary staging, evaluating response, and restaging/post-therapy surveillance. The clinical impact of 18F-FDG PET was determined on a scan basis. Results: A total of 19 patients were recruited and 31 18F-FDG PET scans (including 8 scans performed on a PET/CT scanner) were performed. Positive impacts of scans were found in 36.8% (7/19) for primary staging, 66.7% (2/3) for monitoring response, and 11.1% (1/9) for restaging/post-therapy surveillance. PET excluded falsely inoperable disease defined by MRI in two patients. Aggressive treatment applying to three patients with PET-defined resectable stage IVB disease seemed futile. Two patients died of disease shortly after salvage therapy restaged by PET. With PET monitoring, one stage IVB patient treated by targeted therapy only was alive with good performance. Using PET did not lead to improvement of overall survival of this series compared with the historical control (n = 35) (P = 0.779). Conclusions: The preliminary results suggest that 18F-FDG PET is beneficial in excluding falsely inoperable disease for curative therapy and in making a decision on palliation for better quality of life instead of aggressive treatment under the guidance of PET. PET seems to have limited value in post-therapy surveillance or restaging after failure.

KW - F-FDG

KW - Clinical impact

KW - Malignant mixed müllerian tumor

KW - PET

KW - Uterine carcinosarcoma

UR - http://www.scopus.com/inward/record.url?scp=43349097110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43349097110&partnerID=8YFLogxK

U2 - 10.1007/s00259-007-0533-z

DO - 10.1007/s00259-007-0533-z

M3 - Article

C2 - 17952435

AN - SCOPUS:43349097110

VL - 35

SP - 484

EP - 492

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 3

ER -